Abstract
It is unclear what the risk of allergic reactions is with appropriately given dilute i.v. redback spider antivenom (RBSAV). Ninety-five i.v. administrations of RBSAV referred from January 2001 to November 2006 were reviewed. All patients had local pain, 72% radiating pain, 57% diaphoresis and 39% systemic effects. Four patients (4%) had immediate systemic hypersensitivity reactions: none were severe, one was moderate and three mild. In 32 patients followed up for 2 weeks, three (10%) developed serum sickness. RBSAV given i.v. had a low reaction rate. � 2007 Royal Australasian College of Physicians.
| Original language | English |
|---|---|
| Pages (from-to) | 820-822 |
| Number of pages | 3 |
| Journal | Internal Medicine Journal |
| Volume | 37 |
| Issue number | 12 |
| Publication status | Published - 2007 |
Fingerprint Dive into the research topics of 'Safety of i.v. administration of redback spider antivenom'. Together they form a unique fingerprint.
Cite this
Isbister, G. (2007). Safety of i.v. administration of redback spider antivenom. Internal Medicine Journal, 37(12), 820-822.